- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03713359
Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)
Randomized, Controlled Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC by Technology Transfer From Japan (Phase III)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A phase III, Randomized, control study to compare the immunogenicity and safety of MRVAC vaccine produced by POLYVAC with MR vaccine licensed in Vietnam produced by Serum Institute, India.
Evaluate the safety of MRVAC produced by POLYVAC on Healthy Vietnamese volunteers from 1 - 45 years old.
Evaluate the safety by the ratio of participants having following symptom/signs:
- The ratio of immediate adverse events (local adverse events and systemic adverse events), within 30 minutes after vaccination.
- The ratio of participants having local and systemic adverse events (including unexpected adverse events) occur within 28 days after vaccination.
- The ratio of serious adverse events (SAEs) occur from day 0 to day 28 after vaccination. (SAEs).
Evaluate the immunogenicity of MRVAC produced by POLYVAC on the healthy volunteers from 1 - 45 years.
- The rate of sero-conversion;
- GMT (Geomatric mean Antibody titer) after vaccination.
- Comparison the safety and immunogenicity between MRVAC and control vaccine.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For children 1-2 years old: All subjects must meet all of the following criteria at the time of enroll to stduy:
- Healthy children from 1 year to 2 years old.
- Full-term birth: Pregnancy ≥ 37 weeks.
- Weight at birth is at least 2.5kg.
- Do not get any disease through a clinical examination and ask for medical history before taking part in the study (according to the prescribed information).
- Have not injected Rubella vaccine or a combination vaccine containing Rubella vaccine.
- Have not infected by Rubella before.
- Parents or legal guardians agree to voluntarily consent to their child's participation in the study. Parent or legal guardian is provided basic information about the vaccine as well as benefits, obligations and meaning of participating in the trial. There must be a written consent form for your child to participate.
For people from 1 year to 45 years old:
- Do not get any disease through a clinical examination and ask for medical history before taking part in the study (according to the prescribed card).
- Have not infected by Rubella before.
- For people over 2 years old up to 18 years old: Parents or legal guardians agree to voluntarily consent to their child's participation in the study. Parent or legal guardian is provided basic information about the vaccine as well as benefits, obligations and meaning of participating in the trial. There must be a written consent form for your child to participate.
- For people aged 18 to 45: Completely volunteering to participate in the study after having been provided with basic information about the trial vaccine as well as the benefits, obligations and meaning of the trial participation. Must sign in the consent form to participate in the study.
Exclusion Criteria:
- Fever within 3 days before vaccination (body temperature ≥ 38 degrees Celsius) Persons with congenital malformations, neurological disorders, psychiatric disorders or families with neurological or psychiatric conditions or brain damage.
- Having abnormal immune status or being treated for immunological control; Being immunocompromised as a result of progressive disease treatment.
- Have received immunosuppressive drugs (steroid group) for more than 2 weeks before starting the vaccination.
- Allergy to any vaccine component including hypersensitivity reactions and anaphylactic shock to the antibiotics (Kanamycine and Erythromycin), egg products and gelatin.
- Family history of immunodeficiency.
- Have a history of high fever, seizures
- premature birth (<37 weeks) (applicable to children 1-2 years).
- Malnutrition level 3 or above (applicable to children 1-2 years).
- Have used of gamma globulin, blood transfusions within 3 months before vaccination or gamma glubolin in large doses or the use of immunosuppressive drugs within 6 months before vaccination
- Have used live vaccines within 27 days before vaccination; Have used other vaccines within 4 weeks before entry to study; Use of immunoglobulins or blood products within 3 months before vaccination;
- Is participating in trial other drugs or vaccines; Has an acute or chronic disease that affects the safety (including but not limited to: chronic liver disease, some kidney disease, progressive or unstable neurological disorders, diabetes and organ transplants).
- Having serious acute illness. Responsible doctor or doctor in charge of evaluation consider as unsuitable, such as having abnormal crying ...
- Having plan to go far from the study site between visits. - Being pregnant (for women aged 14 - 45 years)
- Trial subjects must satisfy selection criteria and not be subjected to exclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Trial arm (MRVAC)
Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components: Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection |
Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
|
Active Comparator: Control arm
Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm. Subcutaneous injection |
Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: During 30 minutes and 28 days after only one dose vaccination
|
1. Incidence rate of local adverse event (AE), systemic AE
|
During 30 minutes and 28 days after only one dose vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antibody seroconversion
Time Frame: 42 to 56 days after only one dose vaccination .
|
Positive seroconversion rates of Measles and Rubella neutralization antibody
|
42 to 56 days after only one dose vaccination .
|
Geo-mean antibody titer
Time Frame: Before vaccination and after 42 to 56 days vaccination only one dose
|
Geo-mean antibody titer of both trial arm and control arm
|
Before vaccination and after 42 to 56 days vaccination only one dose
|
Serious adverse event (SAE)
Time Frame: During 30 minutes and 28 days after vaccination only one dose
|
Number of cases occur SAEs
|
During 30 minutes and 28 days after vaccination only one dose
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Dinh H. Duong, Ph.D, Epidemiology department - Vietnam Military Medical University.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRVAC VX.2016.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Signs and Symptoms
-
Seed HealthCurebase Inc.CompletedConstipation | Signs and Symptoms | Digestive Signs and Symptoms | Infrequent or Difficult EvacuationUnited States
-
AB Biotics, SACompleted
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompleted
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedSigns and SymptomsUnited States
-
Jordan Collaborating Cardiology GroupCompleted
-
University of Texas Southwestern Medical CenterCompletedSigns and Symptoms
-
Tim ShiCapital Institute of Pediatrics, ChinaActive, not recruiting
-
University of California, IrvineBeckman Laser Institute University of California IrvineWithdrawn
-
Evalua InternationalPfizer; University of Helsinki; The Finnish Funding Agency for Technology and... and other collaboratorsCompletedSigns and SymptomsFinland
-
Mead Johnson NutritionCompletedSigns and Symptoms, Digestive | Anemia | Respiratory Symptoms
Clinical Trials on Trial arm (MRVAC)
-
Kaohsiung Medical University Chung-Ho Memorial...National Taiwan University HospitalCompleted
-
BiogenTerminatedB-Cell Chronic Lymphocytic LeukemiaUnited States
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
-
Novo Nordisk A/SCompleted
-
University of Colorado, Colorado SpringsRecruitingBlood Pressure | Blood LossUnited States
-
Poitiers University HospitalCompletedWeaning From Mechanical Ventilation | ExtubationFrance
-
University of Illinois College of Medicine at PeoriaOSF Healthcare SystemUnknown
-
Northwell HealthNational Institute on Aging (NIA)RecruitingSleep InsufficiencyUnited States
-
University of MichiganCompletedMetabolic Disease | Adipose TissueUnited States
-
University of VirginiaCompletedUrinary Tract Infections | Urinary Retention